Filtered By:
Specialty: Cardiology
Drug: Pradaxa

This page shows you your search results in order of date. This is page number 10.

Order by Relevance | Date

Total 478 results found since Jan 2013.

Risk of stroke and bleeding in relation to hypertension in anticoagulated patients with atrial fibrillation: a meta-analysis of randomised controlled trials
CONCLUSIONS: Adequate blood pressure management is vital to optimally reduce the risk of stroke in patients with atrial fibrillation. The benefits of NOACs over VKAs, also apply to patients with elevated blood pressure.PMID:33685380 | DOI:10.1080/00015385.2021.1882111
Source: Acta Cardiologica - March 9, 2021 Category: Cardiology Authors: Ralf E Harskamp Wim A M Lucassen Renato D Lopes Jelle C L Himmelreich Gianfranco Parati Henk C P M van Weert Source Type: research

Current status of oral anticoagulant adherence in Japanese patients with atrial fibrillation: A claims database analysis
CONCLUSION: In a real-world Japanese claim data analysis, about 70% of patients under DOAC showed persistence with anticoagulation therapy at 3 years. High adherence to DOACs assessed by PDC (over 90%) persisted to 3 years regardless of the types of DOACs.PMID:33663881 | DOI:10.1016/j.jjcc.2021.02.007
Source: Journal of Cardiology - March 5, 2021 Category: Cardiology Authors: Naoharu Yagi Shinya Suzuki Katsuhiko Nagai Takashi Tanaka Takayoshi Nagahama Takuto Arita Takayuki Otsuka Takeshi Yamashita Source Type: research

Comparison of Direct Oral Anticoagulants versus Warfarin in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves
The objectives of this study were to evaluate the ambulatory utilization of DOACs and to compare the effectiveness and safety of DOACs versus warfarin in patients with AF and BHVs. We conducted a retrospective cohort study at a large integrated health care delivery system in California. Patients with BHVs and AF treated with warfarin, dabigatran, rivaroxaban or apixaban between September 12, 2011 and June 18, 2020 were identified.
Source: The American Journal of Cardiology - January 30, 2021 Category: Cardiology Authors: Lewei Duan, Jason N Doctor, John L Adams, John A Romley, Leigh-Anh Nguyen, Jaejin An, Ming-Sum Lee Source Type: research

A network meta-analysis of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and diabetes mellitus.
CONCLUSION: In patients suffering from AF and diabetes, dabigatran 110 mg (bid) was more likely to become the choice for its performance on preventing systemic embolism or stroke and major bleeding, followed by rivaroxaban 20 mg (QD). PMID: 33432890 [PubMed - as supplied by publisher]
Source: Acta Cardiologica - January 13, 2021 Category: Cardiology Tags: Acta Cardiol Source Type: research

Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Obese Patients with Atrial Fibrillation
ConclusionsIn this large cohort of obese Veterans Health Administration system patients, the use of DOACs resulted in lower hemorrhagic complications than warfarin while maintaining efficacy on ischemic stroke prevention.
Source: Cardiovascular Drugs and Therapy - January 6, 2021 Category: Cardiology Source Type: research

Non–Vitamin K Antagonist Oral Anticoagulants and Factors Influencing the Ischemic and Bleeding Risk in Elderly Patients With Atrial Fibrillation: A Review of Current Evidence
Abstract: Non–vitamin K antagonist oral anticoagulants (NOACs) are a widely prescribed treatment to prevent stroke in patients with nonvalvular atrial fibrillation, and a therapy and preventative measure to prevent recurrences following venous thromboembolism. Optimal use of NOACs requires a thorough knowledge of the pharmacology of these drugs, as well as an understanding of patient factors affecting their use. The 4 NOACs—dabigatran, apixaban, edoxaban, and rivaroxaban are available in a range of doses suitable for differing indications and with a variety of dose reduction criteria. Identification of the correct ...
Source: Journal of Cardiovascular Pharmacology - January 1, 2021 Category: Cardiology Tags: Review Article Source Type: research

Inappropriate Dosing of Direct Oral Anticoagulants in Patients with Atrial Fibrillation
Direct Oral Anticoagulants (DOACs) require dose adjustment based on specific patient characteristics, making them prone to incorrect dosing. The current study aimed to evaluate the prevalence of inappropriate DOAC dosing, its predictors, and corresponding outcomes in a single-center cohort of AF patients. We reviewed all patients with AF treated at Mayo Clinic with a DOAC (Apixaban, Rivaroxaban, or Dabigatran) between 2010 and 2017. Outcomes examined were ischemic stroke /transient ischemic attack (TIA)/embolism and bleeding.
Source: The American Journal of Cardiology - December 28, 2020 Category: Cardiology Authors: Alan Sugrue, David Sanborn, Mustapha Amin, Medhat Farwati, Haarini Sridhar, Azza Ahmed, Ramila Mehta, Konstantinos C. Siontis, Siva K. Mulpuru, Abhishek J. Deshmukh, Bernard J. Gersh, Samuel J Asirvatham, Malini Madhavan Source Type: research

Benefit-Risk Tradeoffs in Assessment of New Drugs and Devices.
Abstract Balancing benefits and risks is a complex task that poses a major challenge, both to the approval of new medicines and devices by regulatory authorities and in therapeutic decision-making in practice. Several analysis methods and visualization tools have been developed to help evaluate and communicate whether the benefit-risk profile is favorable or unfavorable. In this White Paper, we describe approaches to benefit-risk assessment using qualitative approaches such as the Benefit Risk Action Team framework developed by the Pharmaceutical Research and Manufacturers of America, and the Benefit-Risk Framewor...
Source: Circulation - November 17, 2020 Category: Cardiology Authors: Kaul S, Stockbridge N, Butler J Tags: Circulation Source Type: research

Dabigatran vs. Aspirin for Secondary Prevention After Embolic Stroke of Undetermined Source 　- Japanese Subanalysis of the RE-SPECT ESUS Randomized Controlled Trial.
CONCLUSIONS: Dabigatran was putatively associated with a lower relative risk of recurrent stroke compared with aspirin in Japanese ESUS patients. PMID: 33132228 [PubMed - as supplied by publisher]
Source: Circulation Journal - October 30, 2020 Category: Cardiology Authors: Toyoda K, Uchiyama S, Hagihara Y, Kuwashiro T, Mori T, Kamiyama K, Urano Y, Taniguchi A, Nozaki K, Cronin L, Grauer C, Brueckmann M, Diener HC Tags: Circ J Source Type: research

Association of anticoagulant therapy with risk of dementia among patients with atrial fibrillation
ConclusionIn this propensity-matched and -weighted analysis using a real-world population-based cohort, use of NOACs was associated with lower dementia risk than use of warfarin among non-valvular AF patients initiating OAC treatment.
Source: Europace - October 16, 2020 Category: Cardiology Source Type: research

The anticoagulation dilemma and future treatment avenues in patients with breast cancer and atrial fibrillation
Atrial fibrillation (AF) is the most common arrhythmia, with a substantial rise in global incidence and prevalence. Ischemic stroke is a frequent complication of AF, since AF perfectly fulfills Virchow's triad of blood stasis, vascular damage and hypercoagulation, making oral anticoagulation (OAC) obligatory for stroke prevention. Direct oral anticoagulants (DOAC), such as dabigatran, which inhibits thrombin, and apixaban, edoxaban and rivaroxaban, which block the activated coagulation factor X (FXa), have some advantages and are largely replacing coumarin-based OAC.
Source: International Journal of Cardiology - September 30, 2020 Category: Cardiology Authors: Anke C. Fender, Dobromir Dobrev Tags: Editorial Source Type: research